)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Elicio Therapeutics (ELTX) investor relations material
Elicio Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Developing immunotherapies for cancer using AMP technology, with lead candidate ELI-002 7P in Phase 2 for mKRAS-driven pancreatic cancer; interim data review recommended trial continuation with favorable safety profile.
Final event-driven analysis for disease-free survival in the AMPLIFY-7P trial expected in Q4 2025, with preparations for a potential pivotal Phase 3 trial.
Net loss of $10.6M for Q2 2025 and $21.8M for the six months ended June 30, 2025; accumulated deficit reached $215.9M as of June 30, 2025.
Cash and cash equivalents totaled $22.1M at quarter end, with substantial doubt about ability to continue as a going concern beyond Q1 2026 without additional financing.
$10M non-dilutive financing secured in Q2 2025, extending cash runway into Q1 2026.
Financial highlights
Q2 2025 research and development expenses were $7.0M, down year-over-year due to reduced clinical trial manufacturing costs.
General and administrative expenses for Q2 2025 were $3.1M, up year-over-year, mainly from higher professional fees related to financing activities.
Net loss per share was $(0.66) for Q2 2025 and $(1.50) for the six months ended June 30, 2025.
Cash used in operating activities was $19.1M for the six months ended June 30, 2025; net cash provided by financing activities was $22.3M, primarily from equity and debt issuances.
Total assets as of June 30, 2025, were $29.5M; total liabilities were $27.7M; stockholders' equity was $1.8M.
Outlook and guidance
Cash runway expected to fund operations into Q1 2026; additional capital required to continue development programs and operations beyond this period.
Final DFS analysis for Phase 2 AMPLIFY-7P trial anticipated in Q4 2025; End-of-Phase 2 FDA meeting planned to finalize Phase 3 regulatory strategy.
Plans to seek further funding through public/private offerings, debt, or strategic transactions; no assurance of success.
Anticipates increased expenses as clinical and preclinical programs advance and as regulatory and commercialization activities expand.
Plans to expand ELI-002 to additional indications, including mKRAS-positive lung and other cancers.
What efficacy signals inferred from IDMC recommendation?
What is the projected cash burn rate beyond Q1 2026?
How does off-the-shelf approach impact market strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Elicio Therapeutics earnings date
Q3 20257 Nov, 2025
Next Elicio Therapeutics earnings date
Q3 20257 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Elicio Therapeutics Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and infectious diseases. The company specializes in AMP (Amphiphile) platform technology, designed to enhance the delivery of cancer vaccines and immunomodulators to the lymphatic system, improving immune response. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage